Heparin cofactor II is a plasma protein that inhibits thrombin rapidly in the presence of either heparin or dermatan sulfate. We have determined the effects of two glycosaminoglycanbinding proteins, i.e., histidine-rich glycoprotein and platelet factor 4, on these reactions. Inhibition of thrombin by heparin cofactor II and heparin was completely prevented by purified histidine-rich glycoprotein at the ratio of 13 gg histidine-rich glycoprotein/A&g heparin. In contrast, histidine-rich glycoprotein had no effect on inhibition of thrombin by heparin cofactor II and dermatan sulfate at ratios of .128 &g histidine-rich glycoprotein/Mg dermatan sulfate. Removal of 85-90% of the histidine-rich glycoprotein from plasma resulted in a fourfold reduction in the amount of heparin required to prolong the thrombin clotting time from 14 s to >180 s but had no effect on the amount of dermatan sulfate required for similar anticoagulant activity. In contrast to histidine-rich glycoprotein, purified platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of either heparin or dermatan sulfate at the ratio of 2 Mg platelet factor 4/,tg glycosaminoglycan. Furthermore, the supernatant medium from platelets treated with arachidonic acid to cause secretion of platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of heparin or dermatan sulfate. We conclude that histidine-rich glycoprotein and platelet factor 4 can regulate the antithrombin activity of heparin cofactor II.
Introduction
Heparin cofactor II (HCII)' is a glycoprotein in human plasma that rapidly inactivates thrombin in the presence of heparin or dermatan sulfate (1) (2) (3) (4) (5) (6) (7) . HCII is similar to antithrombin III (ATIII) in structure and mechanism of action. Each inhibitor inactivates thrombin by forming an equimolar complex with the protease that is stable upon SDS polyacrylamide gel electrophoresis (4), the two inhibitors appear to have significant amino acid sequence homology in the region of the proteaseAn abstract of this work has been published in Blood. 62:294. 1983. cellulose, carboxymethylcellulose; Polybrene, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide; HCII, heparin cofactor II; HRG, histidine-rich glycoprotein; PF4, platelet factor 4. binding site (8) , and heparin binds to each inhibitor and thereby increases the rate of inhibition of thrombin -1,000-fold (4, 9) . However, HCII and ATIII differ in two important properties: (a) whereas ATIII inhibits all of the serine proteases of the intrinsic coagulation system (10) , the known protease specificity of HCII is restricted to thrombin (2, 4, 6, 7) ; and (b) dermatan sulfate greatly accelerates the reaction between thrombin and HCII but has no appreciable effect on the activity of ATIII (5) .
ATIII appears to be involved in the prevention of intravascular coagulation, since patients with ATIII deficiency often develop recurrent thrombosis (1 1). The mechanism of action of ATIII in vivo has been difficult to study. However, recent experiments indicate that ATIII is activated within the microcirculation, perhaps by binding to heparin-like molecules on the luminal surface of endothelial cells (12, 13) . The site of action of HCII is unknown, although current evidence suggests that it is not a major inhibitor of thrombin within the blood vessels (14) . Nevertheless, HCII is potentially an important inhibitor of thrombin in the extravascular connective tissues where dermatan sulfate is prevalent (15).
Histidine-rich glycoprotein (HRG) in human plasma binds heparin and thereby prevents activation of ATIII in vitro (16) . Similarly, platelet factor 4 (PF4) secreted from platelets during hemostasis binds heparin and neutralizes its anticoagulant effect (17, 18) . The presence of a sufficient quantity of either of these proteins would therefore favor coagulation. In this study, we have investigated the ability of HRG and PF4 to affect the activation of HCII by heparin and dermatan sulfate. We have found that physiological concentrations of both proteins prevent activation of HCII by heparin and that PF4 also prevents activation of HCII by dermatan sulfate. In contrast, HRG has no effect on the ability of dermatan sulfate to activate HCII.
Methods
Materials. Tosyl-Gly-Pro-Arg-p-nitroanilide ( Inhibition of thrombin by HCII and ATIJI. Incubations contained the inhibitor, the glycosaminoglycan, and other reagents at the final concentrations indicated in 100 Ml of 0.15 M NaCl, 0.02 M Tris-HCI, 1 mg/ml polyethylene glycol, pH 7.4. Reactions were initiated by addition of thrombin. At specified times, 100 Ml of a solution containing 0.1 mM tosyl-Gly-Pro-Arg-p-nitroanilide and 0.05 mg/ml 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (Polybrene) in water was added. Hydrolysis of the substrate was stopped after exactly 120 s by addition of 10 Ml of hirudin (200 U/ml), and the absorbance at 405 nm was determined (5) .
The incubations in Figs. 1, 3 , and 4, and Tables I and II contained a molar excess of HCII compared to thrombin, resulting in time courses of inhibition that approximated pseudo-first order kinetics (4, 5) . Heparin and dermatan sulfate were employed at relatively low concentrations, which yielded -100-fold and -16-fold enhancement of the rate of inhibition of thrombin, respectively. Maximum rate enhanements of 800-fold and 1300-fold have been observed with higher concentrations of heparin and dermatan sulfate (5) . Under the experimental conditions, the extent of inhibition of thrombin decreased linearly as the glycosaminoglycan concentration was decreased. No appreciable inhibition occurred in controls in which the glycosaminoglycan was omitted. For convenience, reaction times of 20 s for heparin and 120 s for dermatan sulfate were chosen to produce -50% inhibition of thrombin in the absence of HRG or PF4.
Removal ofHRG from plasma. Human venous blood (4.5 ml) was collected into evacuated tubes containing 0.5 ml of 0.129 M buffered sodium citrate (Vacutainer 6418, Becton-Dickinson, Rutherford, NJ). After removal of the cells by centrifugation, the plasma was absorbed with CM-cellulose by the procedure of Heimburger et al. (24) . The CM-cellulose was cycled according to the manufacturer and suspended in distilled water adjusted to pH 6.0. A portion of the suspension containing 0.4 g (dry weight) of the resin was centrifuged, and the supernatant solution was decanted. The resin was resuspended in 10 ml of plasma (total volume -13 ml) and mixed for 1 h at 22°C. The resin was removed by centrifugation, and the pH of the supernatant plasma was adjusted to 7.0 with 1 M NaOH. HRG was measured in the absorbed plasma by the Laurell immunoelectrophoresis technique (25) using monospecific rabbit anti-HRG antiserum provided by Dr. H. R. Lijnen and Dr. D. Collen (16) .
Determination ofthe thrombin clotting time. 200 Ml of plasma was mixed with 50 ul of dermatan sulfate or heparin in 0.15 M NaCl, 6.6 mg/ml polyethylene glycol, 10 mM CaCl2, and 10 mM imidazole-HC1, pH 7.4. The mixture was warmed to 37°C, 50 Ml of thrombin (-40 nM in the above buffer) was added, and the clotting time was determined with a Fibrometer (Becton-Dickinson Co.).
Treatment ofplatelets with arachidonic acid. Human platelets were washed and resuspended in 0.14 M NaCl, 0.015 M Tris-HCl, 0.0055 M glucose, pH 7.5, at a final concentration of 1.5 X 109 platelets/ml (26). 1 ml of the platelet suspension was incubated for 10 min at 22°C with 100 ul of 0.25 mM arachidonic acid dissolved in 50 mM NaHCO3. The platelets were then removed by centrifugation for 10 min in an Eppendorf microcentrifuge. Control medium was prepared by incubating I ml of platelets with 100 Ml of 50 mM NaHCO3 without arachidonic acid. The concentration of PF4 in the medium was determined with a commercial radioimmunoassay kit (Abbott Laboratories). HRG does not affect the ability of dermatan sulfate to prolong the clotting time ofplasma. The results in Fig. 1 lead to the prediction that variations in the concentration of HRG in plasma should have no effect on the anticoagulant activity of dermatan sulfate. HRG-depleted plasma was prepared by absorption with CM-cellulose as described in Methods. This procedure removed 85-90% of the HRG as assessed by rocket immunoelectrophoresis (Fig. 2) . (16) , depletion of HRG is responsible for this effect, since reconstitution ofthe plasma with purified HRG restores the requirement for the higher heparin concentration. PF4 blocks activation ofHCII by both heparin and dermatan sulfate. Fig. 3 shows the effect of 0-7.7 1AM PF4 (0-60 ,gg/ml) on the extent of inhibition of thrombin by HCII in the presence of 1.7 ,ug/ml heparin or 2.5 ug/ml dermatan sulfate.
Inhibition of thrombin by HCII in the presence of either glycosaminoglycan is prevented by PF4 at concentrations . 1.3 AM. Extrapolations of the linear parts of the curves to 100% thrombin activity suggest that 0.45 AM PF4 is required to neutralize 1.7 ug/ml heparin (i.e., 2 Mug PF4/Mug heparin) and that 0.64 MM PF4 is required to neutralize 2.5 Mg/ml dermatan sulfate (i.e., 2 Mug PF4/Mug dermatan sulfate).
PF4 is secreted from platelets bound to a proteoglycan carrier molecule (27. 28) . To determine whether the proteoglycan interferes with the interaction between PF4 and dermatan sulfate shown in Fig. 3 , we prepared supernatant media from washed human platelets treated with arachidonic acid to cause secretion as well as from control platelets incubated without arachidonic acid. Fig. 4 (Fig. 3) .
Discussion
Dermatan sulfate, heparin, and certain heparan sulfate preparations are able to activate HCII, i.e., to markedly increase the rate of complex formation between thrombin and the inhibitor protein (5). In contrast, while heparin and heparan sulfate inhibitors.
It appears that specific oligosaccharide sequences in dermatan sulfate and heparin are necessary for activity with HCII. Griffith and Marbet have shown that molecules of either glycosaminoglycan that bind to a column of immobilized HCII have higher activities than molecules that do not bind (9) . In both cases, the high-affinity fraction constitutes a minority of the molecules in the initial glycosaminoglycan preparation. Based (Fig. 1) . This result in combination with the data in Table II Table III and Fig. 4 were performed in an attempt to more closely approximate conditions that might be present in vivo. The data in Table III indicate that removal of 85-90% of the HRG from plasma does not affect the concentration of dermatan sulfate required to prolong the clotting time after addition of exogenous thrombin. This result is consistent with the experiment in Fig.  1 , because HCII is the major inhibitor of thrombin in the presence of dermatan sulfate (5). PF4 is secreted from platelets as a tetramer (monomer Mr = 7800) bound to a platelet proteoglycan containing principally chondroitin-4-sulfate (27, 28) . After secretion, PF4 can dissociate from the carrier proteoglycan and bind to other glycoaminoglycans. The relative binding affinities of PF4 to the various glycosaminoglycans are reported to be as follows: heparin > dermatan sulfate > chondroitin-6-sulfate > chondroitin-4-sulfate (17) . Fig. 4 suggests that the carrier proteoglycan does not prevent binding of PF4 to dermatan sulfate, since activation of HCII by dermatan sulfate was prevented by supernatant medium from stimulated platelets. We have not investigated the possibility that other secreted proteins which bind heparin with lower affinity than does PF4 (e.g., low-affinity PF4, fl-thromboglobulin, and thrombospondin) (32, 33) effectively compete with HCII for binding to dermatan sulfate. Although HCII is a very potent inhibitor of thrombin in vitro, its physiological function is unknown. When thrombin is injected intravenously into experimental animals or perfused with plasma through a microvascular preparation, it is primarily inhibited by ATIII (12, 14) . This suggests that the normal role of HCII is not to inhibit intravascular thrombin. Nevertheless, dermatan sulfate given intravenously prevents formation of thrombi in rabbits, apparently by activating HCII within the blood vessels (34) . Physiologically, however, HCII may inhibit thrombin in extravascular sites where dermatan sulfate is prevalent and thereby regulate activities of the protease such as mitogenesis (35) or chemotaxis (36) . Modulation 
